Recombinant Human APOC3 Protein，His

APOC3, or Apolipoprotein C-III, is a protein primarily produced in the liver and small intestine, playing a crucial role in lipid metabolism and influencing triglyceride levels in plasma. Recent studies have illuminated its significant involvement in various metabolic disorders, including hypertriglyceridemia, cardiovascular diseases, and type 2 diabetes. As a critical component of lipoproteins, APOC3 acts by inhibiting lipoprotein lipase, thus impeding the clearance of triglyceride-rich lipoproteins from the bloodstream. This has drawn considerable attention to its potential as a therapeutic target, as modulation of APOC3 levels could lead to innovative strategies for managing lipid disorders. Furthermore, genetic variants of APOC3 have been associated with altered lipid profiles and cardiovascular risks, illustrating its importance in personalizing treatment approaches. Research into recombinant forms of APOC3 protein has expanded, enabling investigations into its structure-function relationships, interactions with other lipoproteins, and its role in related metabolic pathways. Advances in recombinant protein production techniques have paved the way for detailed studies into the mechanistic aspects of APOC3, providing insights that could eventually facilitate the design of APOC3-targeted therapies aimed at reducing cardiovascular risk and improving metabolic health. As understanding of APOC3 continues to evolve, it holds promise not only for elucidating the complexities of lipid metabolism but also for developing novel interventions to combat metabolic diseases.